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Introduction
The most common inherited condition associated with colorec-
tal cancer is Lynch syndrome (LS), formerly known as hereditary
non-polyposis colorectal cancer (HNPCC). The syndrome is
caused by a defect in one of the mismatch repair (MMR) genes
(MLH1, MSH2 /Epcam, MSH6, or PMS2) [1]. Besides a high life-
time colorectal cancer risk, MMR-gene mutation carriers also
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ABSTRACT
Background and study aims Lynch syndrome (LS) pa-
tients have an increased risk of small bowel cancer. The
question is whether surveillance will lead to early detection
of (pre)malignant lesions. We recently reported on preval-
ence of small bowel neoplasia (SBN) in LS patients as asses-
sed by video capsule endoscopy (VCE). The aim of this pro-
spective study was to determine the incidence of SBN.
Patients and methods Asymptomatic LS patients who
underwent a VCE were invited to undergo a second VCE
procedure 2 years later. If abnormalities or polypoid lesions
larger than 1cm were detected, subsequent endoscopic
procedures were performed.
Results A total of 155 (78%) of the initial 200 patients un-
derwent a second VCE procedure after a mean of 2.2 (range
1–6) years. In 17 of the 155 (11%) patients possibly signif-
icant lesions were detected, which required further investi-
gation by means of gastroduodenoscopy (n =8) or balloon-
assisted endoscopy (n =9). These procedures revealed no
SBN.
Conclusion No SBN was found after 2 years. Surveillance
of the small bowel by VCE does not seem to be warranted
in asymptomatic LS patients.
This study was registered in the Clinical Trials.gov registry
with identifier NCT00898768.
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have an elevated risk of developing various extracolonic malig-
nancies, including small bowel cancer [2].
Compared with the general population, the relative risk of
developing small bowel carcinoma is more than 100 in LS pa-
tients, with an estimated lifetime risk of 4.2% [3, 4]. Like LS-
associated colorectal cancer, it also occurs at a relatively early
age. Retrospective analyses showed a median age at diagnosis
of 39 (range 11–81) years [3, 5]. Recently, we showed that the
prevalence of small bowel neoplasia (SBN) in asymptomatic LS
patients as assessed by video capsule endoscopy (VCE) was
markedly lower than previously estimated [6, 7]. SBN was pres-
ent in only 3 of the 200 patients (1.5%) who underwent a VCE
procedure (2 duodenal adenocarcinomas and 1 duodenal tubu-
lovillous adenoma with low grade dysplasia) [6].
LS patients benefit from colonic surveillance [8, 9]. In order
to determine whether they might also benefit from surveillance
of the small bowel more data are needed. We therefore per-
formed a follow-up study in the original study cohort to assess




As reported earlier [6], this study was a nationwide prospective
multicenter trial in the Netherlands that aimed to assess the
prevalence and incidence of SBN in asymptomatic LS patients
by VCE. The study was registered in the ClinicalTrials.gov regis-
try (NCT00898768). The study protocol was approved by the
local Medical Ethics Committee of the University Medical Cen-
ter Groningen and by all participating centers.
Study procedures and population
All 200 previously included asymptomatic proven carriers of a
MMR-gene mutation (MLH1, MSH2 /Epcam, MSH6, or PMS2)
aged between 35 and 70 years at the date of inclusion were in-
vited for a second VCE procedure 2 years after the first proce-
dure, unless in the meantime exclusion criteria were met. Be-
cause exact data on the prevalence and incidence of small bow-
el neoplasms are scarce, the interval of 2 years was chosen
based on the recommendations made for colonoscopic surveil-
lance.
Exclusion criteria were: (1) previous small bowel surgery or
large bowel surgery involving the ileocecal valve; (2) a strong
clinical suspicion of small bowel stricture; (3) pregnancy; and
(4) presence of any psychological, familial, sociological, or geo-
graphical condition potentially hampering compliance with the
study protocol and follow-up schedule.
A standardized regimen of 2 L bowel preparation based on
polyethylene glycol (PEG) electrolyte solution was given, start-
ing the day before the procedure. The video capsules used were
supplied by Given Imaging (Yoqneam, Israel), with a recording
time of 8 hours. The VCE recordings were reviewed by the local
VCE-responsible endoscopist and by the study coordinator
(JJK), to limit the possibility of missing an important lesion.
The examination was considered complete if cecal visualization
was achieved. To evaluate the quality of bowel preparation, a
semi-quantitative evaluation by means of a grading scale
(poor, moderate or good) was used. Small bowel preparation
was defined as good if the mucosa was generally clean with no
or minimal residual fluid and debris; moderate, if the visualiza-
tion of the mucosa was impaired because of moderate fluid and
debris; and poor if the mucosa visualization was highly limited
because of excessive residual fluid and debris. If polyps with an
estimated size of at least 1 cm or significant abnormalities were
seen on the VCE recordings, additional endoscopic procedures
were performed. Significant abnormalities were defined as: (1)
polyps of any size not resembling lymfangiectasia(s) (2) ulcera-
tive lesions or (3) abnormalities with unknown significance (like
hematin). The subsequent endoscopic procedure depended on
the estimated localization of the detected lesion: a gastroduo-
denoscopy was scheduled when lesions were identified in the
duodenum; if abnormalities were seen within the first two-
thirds of the capsule recording time an oral/antegrade bal-
loon-assisted enteroscopy (after fasting from midnight) was
chosen and in the other cases an anal/retrograde balloon-assis-
ted enteroscopy (after bowel preparation with PEG) was per-
formed. The aim of these endoscopic procedures was to re-
move polypoid lesions, or to obtain histology if removal was
not possible. Biopsies were also taken if the endoscopist had
doubts with respect to the benign nature of lesions.
When no lesions were found with the balloon-assisted en-
teroscopy and the lesion was considered to be not definitely
reached, the maximum point of introduction was marked with
ink and the alternative approach was scheduled.
Endpoints
The primary endpoint of this study was incidence of neoplastic
small bowel lesions, defined as the percentage of patients with
a small bowel adenoma or carcinoma. The following lesion
characteristics were included: morphology according to the
Paris Classification [10], size, location, and histology. The sec-
ondary endpoint was the number of complications following
capsule endoscopy and subsequent endoscopic procedures.
Statistical analysis
IBM SPSS 23 (SPSS, Chicago, IL) was used for all data analyses.
Descriptive statistics were used to determine demographic
characteristics and to analyze VCE results.
Results
Of the original cohort of 200 patients, 155 (78%) patients con-
sented to undergo a second VCE procedure. The reasons for ex-
clusion are shown in ▶Fig. 1.
Two patients were excluded because of SBN detected at the
first VCE. These findings were described in our previous report
[6]. One patient was diagnosed with a TisN0Mx duodenal carci-
noma and subsequently underwent a pylorus-preserving pan-
creaticoduodenectomy. Histological examination of the resect-
ed duodenum showed high-grade dysplasia at multiple loca-
tions. The other patient had a tubulovillous duodenal adenoma
with low-grade dysplasia that was removed by endoscopic mu-
cosal resection (EMR). Afterwards annual surveillance was
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scheduled in the form of a gastroduodenoscopy with biopsy
and VCE. Four years later, a flat polypoid lesion was detected
at the location of the previous EMR. Endoscopic removal of the
lesion was attempted, which failed due to nonlifting. A surgical
resection was ultimately performed for this lesion. Histology
again showed tubulovillous adenoma with low-grade dysplasia.
The included patients had a mean age of 51.6 (range 36–
71) years and 63 (40.6%) were male. All mutations types were
represented: MLH1 (n=39), MSH2 (n=57), Epcam (n=2), MSH6
(n=54), and PMS2 (n=3).
The second VCE procedure was performed after a mean in-
terval of 2.2 years (with a range of 1–6 years) after the first
procedure. A total of 22 patients underwent a follow-up proce-
dure outside the predetermined surveillance interval. In 6 pa-
tients, the second VCE procedure was performed earlier than
scheduled, namely 1 to 1.5 years after the first procedure. In
16 patients, the second VCE was performed later than sched-
uled; in 9 patients after 3 to 4 years and in 7 patients after 4
years. Despite this deviation from the protocol, these patients
were included in the analysis.
Performance of VCE
The small bowel was completely examined during VCE record-
ing time in 134 patients (86%). In 3 of the patients the exami-
nation was incomplete due to technical errors. Mean gastric
and small bowel transit times were 40 (1–490) minutes and
243 (41–464) minutes, respectively. Bowel preparation was
good in the majority of patients (88%); in 11% it was moderate;
and in 1% it was poor. Besides possible polypoid lesions, discus-
sed below, other findings were also detected in 31 patients:
lymfangiectasia(s) (n =14), Brunner’s glands (n =3), angiodys-
plasia(s) (n =6), erosion(s) (n =8), intestinal metaplasia (n=1),
swollen mucosa (n=1), a tattoo mark, (n =1) and erythema
(n=2). In 2 patients VCE also demonstrated polypoid lesions
of the colon.
Incidence of neoplasia
VCE detected abnormalities in 19 patients. In 2 patients, the le-
sions were considered insignificant because of the small size
(smaller than 1 cm) and benign aspect. All significant lesions
except for one were proximally located. Further endoscopic
procedures were performed in 17 patients (▶Table1 and
▶Fig. 1): 8 patients underwent gastroduodenoscopy and 9 un-
derwent (single or double) balloon-assisted enteroscopy.
In 7 of 13 patients with possible (mostly protruded) polypoid
lesions detected by VCE, no lesions were encountered endo-
scopically. The VCE results were considered false-positive since
the location of the lesion seen on VCE was considered to be
within reach of the endoscopy and no further procedures were
performed. In the remaining 6 patients with polypoid lesions on
VCE, endoscopic abnormalities were found. In 2 of these pa-
tients, benign-appearing lesions were found and no biopsies
were taken: one had a thickened fold with a benign aspect and
the other had a hypertrophic Brunner’s gland. In the other 3 pa-
tients with confirmed polypoid lesions a biopsy was taken, as
well as in 1 patient with swollen mucosal folds. Histologic ex-
amination showed normal mucosa (n =2), lymphoid hyperpla-
sia (n=1), and a fundic gland polyp (n =1). No SBN was found.
In 4 patients, endoscopic procedures were performed be-
cause of other abnormalities.
Of the 3 patients with hematin seen on VCE, 1 had non-
specific hematin confirmed by gastroduodenoscopy, another
had a Helicobacter pylori-associated gastritis, and in the third
no abnormalities were found. In 1 patient with a possible ulcer
in the jejunum, a double balloon-assisted enteroscopy was per-
formed, which showed no abnormalities.
Complications
No complications were observed during or following the VCE
procedure or the subsequent endoscopic procedures.
Included patients for first VCE n = 200
Analyzed patients for second VCE n = 155
Normal or insignificant 
VCE findings n = 136
▪ No abnormalities 
 (n = 105)
▪ Insignificant lesions 
 (n = 31)
Polyp or abnormalities 
on VCE n = 19
▪ Polyp 
 (n = 15, 16 polyps)
▪ Other abnormalities 
 (n = 4)
No additional procedure 
n = 2
Other procedures n = 17
▪ Gastroduodenoscopy  
 (n = 8)
▪ Balloon assisted 
 endoscopy (n = 9)
 – Single balloon, 
  antegrade (n = 3)
 – Double balloon 
  (n = 6)
  – Retrograde (n = 1)
  – Antegrade (n = 5)
Excluded patients n = 45
▪ Small bowel stricture (n = 1)
▪ Deceased (n = 3) 
 – Postoperative after surgery for SBN (n = 1)
 – Colorectal carcinoma (n = 1)
 – Unknown cause of death (n = 1)
▪ SBN in first VCE (n = 2)
▪ Withdrawal patient (n = 17)
▪ Patient moved (n = 1)
▪ Logistical reasons (n = 18)
▪ Other malignancy (n = 3)
 – Urothelial cancer (n = 2)
 – Multiple myeloma (n = 1)
▶ Fig. 1 Consort diagram. SBN: Small bowel neoplasia; VCE: Video
capsule endoscopy
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Discussion
In the first part of this study, published earlier, we demonstrat-
ed a prevalence of small bowel neoplasia of 1.5% (3/200) in
asymptomatic LS patients. Neoplastic lesions were all detected
in males over 50 years of age, and all lesions were located in the
duodenum. Two of the three neoplastic lesions were detected
by VCE. During follow-up, it became clear that 1 T2N0M0 ade-
nocarcinoma had been missed by VCE [6].
The aim of the present study was to determine the incidence
of SBN in asymptomatic LS patients by VCE a mean of 2 years
after our recent analysis of the prevalence in the same cohort.
We found that after biennial surveillance none of the 155 pa-
tients had developed SBN or were diagnosed with a potentially
missed lesion by the first VCE. No complications were observed
due to VCE.
This is the first study to prospectively assess the incidence of
SBN in LS patients. In the general population, the reported inci-
dence of small bowel cancer is 1.4 per 100000 for men and 1.0
per 100000 for women in the United States[11]. In our study
cohort, the incidence was 0. An explanation for this difference
might be that the study group was too small to determine the
incidence of neoplasia. Also, the predetermined study interval
of 2 years may have been too short to develop neoplasia be-
cause the SBN prevalence appeared to be lower than previously
expected [6]. It is also possible that neoplastic lesions were mis-
sed by VCE. The other limitations of the study design were al-
ready discussed in detail with the baseline results [6]. One other
minor limitation was the fact that no biopsies were taken in 1
patient with a thickened duodenal fold. This probably represen-
ted hypertrophic Brunner’s gland tissue, but that was not con-
firmed by histology. The endoscopic assessment of lesions was
left to the appreciation of lesions by the endoscopist.
Should surveillance of the small bowel by VCE become
standard protocol for LS patients? VCE can be considered as a
safe endoscopic procedure and is generally well tolerated.
However, initial prevalence and 2-year incidence of SBN were
low in our studies. In addition, VCE demonstrated a high num-
ber of false positive results, and we also observed 1 case of SBN
that was missed by the first VCE [6]. In conclusion, our data do
not support use of VCE as a surveillance technique for examin-
ing the small bowel in asymptomatic LS patients.
▶ Table 1 Results of further procedures investigating possible lesions detected by VCE.
Age, sex Mutation VCE finding Location Procedure Final diagnosis
64, F MSH2 Subpedunculated polyp > 10mm Jejunum DBE antegrade No abnormalities
59, M MLH1 Sessile polyp 6–9mm Duodenum Gastroduodenoscopy Brunner’s gland (No histology)
61, F MSH2 Subpedunculated polyp < 5mm Duodenum Gastroduodenoscopy Pedunculated polyp < 5 mm:
Normal mucosa
54, M MLH1 Dubious polyp < 5mm Ileum DBE retrograde No abnormalities
40, F MSH6 Pedunculated polyp > 10mm Jejunum SBE antegrade Pedunculated polyp 6–9 mm:
Lymfoid hyperplasia
38, F MLH1 Two lesions
1. Pedunculated polyp < 5mm
2. Pedunculated polyp < 5mm
Stomach
Duodenum
SBE antegrade Pedunculated polyp < 5 mm:
Fundic gland polyp
No abnormalities
44, M MSH6 Dubious polyp < 5mm Jejunum DBE antegrade Thickened non-suspicious mucosa
(No histology)
60, F PMS2 Pedunculated polyp < 5mm Jejunum SBE antegrade No abnormalities
54, F MLH1 Flat elevation of mucosa < 5mm Duodenum Gastroduodenoscopy No abnormalities
39, F MSH6 Subpedunculated polyp 6–9mm Duodenum Gastroduodenoscopy Swollen mucosa: Normal mucosa
55, F MSH2 Subpedunculated polyp 6–9mm Jejunum DBE antegrade No abnormalities
67, M MSH6 Flat elevation of mucosa < 5mm Jejunum DBE antegrade No abnormalities
44, M MSH6 Lymphangiectasia or flat elevation
of mucosa < 5mm
Duodenum Gastroduodenoscopy No abnormalities
57, M MSH6 Hematin Duodenum Gastroduodenoscopy No abnormalities
63, M PMS2 Hematin Stomach Gastroduodenoscopy Aspecific hematin
40, F MLH1 Ulcer Jejunum DBE antegrade No abnormalities
49, M MSH2 Hematin Stomach Gastroduodenoscopy Multiple small elevated lesions
antrum: H. pylori- associated
chronic focally active gastritis
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